Galmed Pharmaceuticals
GLMD
17 hedge funds and large institutions have $10M invested in Galmed Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 18 → 17 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
44% less capital invested
Capital invested by funds: $17.7M → $10M (-$7.72M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$897K |
| 2 |
Goldman Sachs
New York
|
+$98.4K |
| 3 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
+$87.5K |
| 4 |
Morgan Stanley
New York
|
+$87.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.66M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$1.39M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.01M |
| 4 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$984K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$678K |
GLMD Hedge Fund Activity: Q3 2014 in Review
17 of the 3,454 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2014, worth a combined $10M — down 44% from $17.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GLMD and 7 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was Wells Fargo, opening a new position worth an estimated $897K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.66M sold.
- 17 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2014, down from 18 in Q2 2014.
- Funds reported $10M of Galmed Pharmaceuticals stock for Q3 2014, down 44% quarter-over-quarter.
- 7 funds opened new Galmed Pharmaceuticals positions in Q3 2014 and 8 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2014 was Wells Fargo, an estimated $897K added.
- The largest Galmed Pharmaceuticals seller in Q3 2014 was Sphera Funds Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q3 2014.